Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,144
datasets available to search
ShareScore release 0.9.0
Dataset results
6,144 results for “cancer treatment”
Time series transcriptomes resolve metabolic pathways underlying crocin's anti-cancer activity | Dataset: sequencing reads (2,6,12,24 hr crocin treatments)
<p><span>Natural products like saffron show promise in treating hepatocellular carcinoma (HCC), but their mechanisms remain unclear. Here, we used time-series transcriptomics to elucidate crocin's anti-cancer mechanisms in HCC cells. We treated HepG2 cells with 1 and 2 mM crocin for 2, 6, 12, and 24 hours and analyzed transcriptomic profiles at each timepoint. The strongest transcriptional response occurred at 2 hours with 1 mM crocin, with diminishing effects at later timepoints. We observed upregulation of metabolic-, adhesion-, and endocytosis-related genes across all timepoints. Pathway analysis revealed activation of DNA damage checkpoints and senescence while proliferation pathways were suppressed. Notably, 52 genes involved in non-alcoholic fatty liver disease were downregulated at 24 hours (FDR p = 8 × 10⁻⁸), suggesting reversal of carcinogenic pathways. Strikingly, crocin consistently downregulated spliceosomal machinery genes across all timepoints while upregulating senescence and autophagy pathways. This spliceosome targeting represents a clinically relevant mechanism, as aberrant splicing drives oncogenesis in more than 90% of cancers. The transcription factor PAX5 was significantly upregulated while oncogenic ELK1 targets were downregulated. Our findings show that crocin treatment is accompanied by HCC cell senescence induction through coordinated spliceosome disruption and metabolic reprogramming, providing novel therapeutic targets for hepatocellular carcinoma.</span></p> <p><strong><span>Keywords: </span></strong><span>Hepatocellular carcinoma (HCC), crocin, transcriptomics, spliceosome, senescence, natural anti-cancer compounds</span></p>
HINC dataset from: Homeopathic treatment as an add-on therapy may improve quality of life and prolong survival in patients with non-small cell lung cancer: A prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study
<p class="CxSpFirst"><b>Background:</b> Patients with advanced non-small cell lung cancer (NSCLC) have limited treatment options. Alongside conventional anticancer treatment, additive homeopathy might help to alleviate side effects of conventional therapy. The aim of the present study was to investigate whether additive homeopathy might influence quality of life (QoL) and survival in NSCLC patients.</p> <p class="CxSpMiddle"><b>Methods:</b> In this prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter, phase III study, we evaluated the possible effects of additive homeopathic treatment compared with placebo in NSCLC stage IV patients with respect to QoL in the two randomized groups and survival time in all three groups. Treated patients visited the outpatients' centers every 9 weeks. 150 Patients with stage IV NSCLC were included in the study. 98 received either individualized homeopathic remedies (n=51) or placebo (n=47) in a double-blinded fashion. 52 control patients without any homeopathic treatment were observed for survival only. The constituents of the different homeopathic remedies were mainly of plant, mineral or animal origin. The remedies were manufactured by stepwise dilution and succussion, thereby preparing stable Good Manufacturing Practice grade formulations.</p> <p class="CxSpMiddle"><b>Results:</b> QoL as well as functional and symptom scales showed significant improvement in the homeopathy group when compared with placebo after 9 and 18 weeks of homeopathic treatment (p<0.001). Median survival time was significantly longer in the homeopathy group (435 days) vs placebo (257 days; p=0.010) as well as vs control (228 days; p<0.001). Survival rate in the homeopathy group differed significantly from placebo (p=0.020) and from control (p<0.001).</p> <p class="CxSpMiddle"><b>Conclusion:</b> QoL improved significantly in the homeopathy group compared with placebo. In addition, survival was significantly longer in the homeopathy group versus placebo and control. A higher QoL might have contributed to the prolonged survival. The study suggests that homeopathy positively influences not only QoL but also survival. Further studies including other tumor entities are warranted.</p>
Dataset for comparison of the efficacy of different drug combinations for the treatment of patients with triple negative breast cancer.
<p>Dataset for comparison of the efficacy of different drug combinations for the treatment of patients with triple negative breast cancer.</p>
Search strategies for 177 lu-PSMA in the treatment of metastatic castrate-resistant prostate cancer
<p>The dataset includes the complete, reproducible search strategies for all literature databases searched during this project. The search strategies were designed to answer the following research questions:</p> <p><strong>RQ1.</strong> Does the use of radioligand therapy using <sup>177</sup>Lu-PSMA lead to improved overall survival and progression-free survival, compared with other available treatment(s) in patients with metastatic, castrate-resistant prostate cancer?</p> <p><strong>RQ2.</strong> Does the use of radioligand therapy using <sup>177</sup>Lu-PSMA lead to improved quality of life or symptom control, compared with other available treatment(s), in patients with metastatic, castrate-resistant prostate cancer?</p> <p><strong>RQ3. </strong> What is the risk of adverse events and toxicity associated with radioligand therapy using <sup>177</sup>Lu-PSMA, compared with other available treatment in patients with metastatic, castrate-resistant prostate cancer?</p>
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
ClinicalTrials.gov study NCT00995488. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
ClinicalTrials.gov study NCT04406857. IPD Sharing: YES. Countries: 1. Publications: 1.
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
ClinicalTrials.gov study NCT00276744. IPD Sharing: NO. Countries: 1. Publications: 1.
MEtronomic TrEatment Option in Advanced bReast cAncer
ClinicalTrials.gov study NCT02954055. IPD Sharing: NO. Countries: 1. Publications: 8.
The Exercise And Colorectal Cancer Treatment Trial
ClinicalTrials.gov study NCT03975491. IPD Sharing: YES. Countries: 1. Publications: 3.
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
ClinicalTrials.gov study NCT03775486. IPD Sharing: YES. Countries: 12. Publications: 1.
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
ClinicalTrials.gov study NCT01937117. IPD Sharing: NO. Countries: 1. Publications: 2.
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-
ClinicalTrials.gov study NCT04639245. IPD Sharing: NO. Countries: 1. Publications: 1.
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
ClinicalTrials.gov study NCT00463060. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
ClinicalTrials.gov study NCT00111839. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
ClinicalTrials.gov study NCT00937560. IPD Sharing: Not stated. Countries: 9. Publications: 1.
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
ClinicalTrials.gov study NCT02288247. IPD Sharing: YES. Countries: 16. Publications: 1.
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
ClinicalTrials.gov study NCT01754987. IPD Sharing: NO. Countries: 1. Publications: 1.
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
ClinicalTrials.gov study NCT04291612. IPD Sharing: YES. Countries: 4. Publications: 1.
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ClinicalTrials.gov study NCT02466971. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
ClinicalTrials.gov study NCT04439214. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.